[Piracetam in severe cranio-cerebral injuries].
A group of 100 patients treated immediately following a cranio-cerebral injury was analyzed. The patients, administered piracetam either in an intravenous infusion (GCS 3-8) or orally (GCS above 9), were divided into groups depending on the dose and clinical status. Piracetam participates in the activity of the majority of neurotransmitters, increases glucose and oxygen consumption in the ischaemic nervous tissue and increases blood flow through cerebral terminal vessels. In cranio-cerebral injuries, piracetam is employed to achieve cytoprotection and improve cerebral blood flow. In patients with neurological deterioration following the administration of 6-10 mg/day, no good results were obtained. A dose of 24-30 mg/day had a significant positive effect on therapeutic results providing certain conditions were met, such as ensuring proper partial oxygen pressure (oxygen therapy) and proper blood glucose levels. The use of piracetam is justified immediately after an injury; after the discharge oral piracetam therapy is recommended.
Gościński
I
I
Kliniki Neurotraumatologii Instytutu Neurologii Collegium Medicum UJ.
Sliwonik
S
S
Sondej
T
T
Kwiatkowski
S
S
Moskała
M
M
Cichoński
J
J
Wegrzyn
D
D
Uhl
H
H
D001930:Brain Injuries / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007275:Injections, Intravenous; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010889:Piracetam / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome
D018696:Neuroprotective Agents; D010889:Piracetam